AzTrials
AzTrials

Overactive BladderNCT00437528

Safety and Applicability Study of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity

An observational study of Overactive Bladder and Urge Urinary Incontinence, run by Rambam Health Care Campus at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

A novel sensor (a device named sensurine)was developed in the aim of real- time measurement of bladder volume. The sensurine device is a wearable, fully passive, non-invasive and compact heat flow sensor (patent pending) and electronic control unit. Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
How many people
10 participants
Where
1 siteIsrael
Study dates
Nov 2006to Dec 2007
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • All subjects will be aged 18-50, active, in good general health and without urinary complaints or documented urinary tract dysfunctions

Who cannot join

  • Pregnancy, breast feeding, known allergic sensitivity to medical adhesive tapes, cognitive incompatibility and mental incompetence

Trial locations and contacts

1 site in 1 country.

Israel1 site, 1 recruiting
  • Rambam Healthcare Campus

    Haifa, Northern District, 31096

    Ilan Gruenwald, MD

    Recruiting

Other trials in Israel

About this study

Official title: Phase I Study for Evaluating the Safety and Applicability of a Novel Heat Flow Sensor Unit for Measuring Urinary Bladder Capacity

A novel sensor (a device named sensurine)was developed in the aim of real- time measurement of bladder volume. The sensurine device is a wearable, fully passive, non-invasive and compact heat flow sensor (patent pending) and electronic control unit. The device will serve as a tool for managing and treating bladder dysfunction (by behavioral treatment), such as overactive bladder without incontinence, urge incontinence and voiding difficulties. In this phase I of the clinical trial the sensor unit will be tested for technological feasibility demonstration and for collecting design data.

Read the detailed description

The Primary objectives are to asses the safety and the physical performance of the SenseUrine's sensor unit and to validate the concept of determining bladder volume by measuring heat flow. The Secondary objective is to optimize the device accuracy Primary endpoints: To show that the sensor has no negative effect on the subject, to determine bladder urine volume, based on the sensor's signals, in an accuracy of ±10% compared to the actual volume. Secondary endpoint - to determine bladder urine volume, in an accuracy of ±10%, in different ambient conditions (temperature and clothing).

Inclusion criteria - All subjects will be aged 18-50, active, in good general health and without urinary complaints or documented urinary tract dysfunctions. Exclusion criteria - Pregnancy, breast feeding, known allergic sensitivity to medical adhesive tapes, cognitive incompatibility and mental incompetence.

On the first visit, the subject will sign an informed consent form. A medical intake including demographic data will be collected. Stage 1 will serve for basic testing of the sensor unit and for measuring the maximal and minimal bladder volume. The sensor will be attached to the lower abdomen wall and checked for functionality. Each subject will fill up his bladder (by drinking water) until sensing a strong urge to void. The subject will then void until he is empty into a measurement cup. Ultrasound measurement (US) of bladder volume, and sensor signal will be read and recorded by a standard miliVoltmeter just before and immediately after emptying the bladder. Sensor, US and cup measurement readings will not be done by the same investigator. Continuing to stage 2 will depend on the preliminary results (sensor readings compared to the measured volume and US readings) determining feasibility.. Stage 2 will serve for measuring the dynamics of bladder heat conductivity during the filling and voiding phases. On the 2nd visit the subject will fill up his bladder by gradually drinking 500CC of water (over 60-90 minutes) until sensing a strong urge to void. The subject will drink an additional 50-100CC of water and wait around 10 minutes in the aim of achieving maximal bladder capacity. The sensor signals will be recorded from the beginning of this bladder filling stage every 5-10 minutes. Then, the subject will be requested to void in a controlled manner and to intentionally stop urinating after emptying 50-100CC of urine (voided volume will be determined by the measurement cup). The controlled voiding of 50-100CC will be repeated until the bladder is empty. The sensor signals will be read and recorded during both stages. Visit 3 will be performed in the same manner but in different positions during measurements (supine-on the back, sides and front, sitting, and standing). Visit 4 (final visit) will serve for demonstrating the sensor unit's performance in different ambient temperature and clothing. Two subjects will be randomly selected to examine the sensor in an ambient of 15ºC (this will be controlled by an air-conditioned room with an external thermometer) for measuring the dynamic range (maximal and minimal bladder capacity). The same will be done at room temperature twice- with light and heavy clothing. The other 2 subjects will be randomly selected to examine the sensor's performance in an ambient of 40ºC (hot temperature will be achieved by an electric heater in a small room controlled with an external thermometer) for measuring the dynamic range (maximal and minimal bladder capacity). The same will be done at room temperature twice- with light and heavy clothing.

All output signals will be logged and processed to show the correlation between the calculated heat conductance of the bladder and the volume. A table consisting the calculated indexes of conductivity vs. bladder volumes will be designed.

General: 10 subjects will be recruited by advertisement with notification of some compensation for their time and travel to the study site. Every session will last about 4 hours long. In each working day 3-5 subjects will participate and the total trial period is expected to be approximately 20 working days.

Keywords
Heat flow, Sensor, Overactive bladder, Urinary incontinence
Medical subject headings
Urinary Bladder, Overactive, Urinary Incontinence, Urge, Enuresis, Urinary Incontinence

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Feb 2007 (estimated)
  2. Study startNov 2006
  3. Study completionDec 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Time perspective
Prospective
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00437528
Sponsor's protocol ID
2456_CTIL
Status last verified
Feb 2007
First submitted
19 Feb 2007
Last updated
17 May 2007
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Overactive Bladder and Urge Urinary Incontinence, run by Rambam Health Care Campus at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 May 2007. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ilan Gruenwald, MD (00972-54-4-474341, i_gruenwald@rambam.health.gov.il), or a site near the patient. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2007.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in